DOCSLIB.ORG

Biovision's Antibiotics

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Biovision's Antibiotics BioVision’s Antibiotics BioVision offers a wide range of high-quality, ready-to-use selective Antibiotics and anti-Microbial agents for maintenance of prokaryotic and eukaryotic cells. Many of our antibiotics are also available in solution (sterile) for customer’s convenience and is ready-to-use for cell culture applications to prevent the growth of contaminating bacteria and fungi. All the products under this sub category are shown below. Product Highlights: • Highly Purified Broad Spectrum of Antibiotics to choose from • Available as Solid and In Solution (Sterile) forms • Broad Spectrum of Protein Synthesis Inhibitors, Protein Kinase Inhibitors, DNA and RNA Synthesis or Matrix Metalloproteinase Inhibitors and Selection agents for both Prokaryotic and Eukaryotic Cells Product Name Cat. No. Size CAS # A23187 1501 10 mg 52665-69-7 Amikacin B1514 Varies 37517-28-5 Amikacin Disulfate B1513 Varies 39831-55-5 Amphotericin B, USP 2497 Varies 1397-89-3 Ampicillin sodium 2484 Varies 69-52-3 www.biovision.com 155 S. Milipitas Blvd, Milipitas, CA 95035 T: 408-493-1800 F: 408-493-1801 Toll Free: 800-891-9699 (US Only) Product Name Cat. No. Size CAS # EZSolution™ Ampicillin sodium, Sterile-Filtered 2499 10 ml 69-52-3 Ampicillin trihydrate 2483 Varies 7177-48-2 Anisomycin 1549 10 mg 22862-76-6 Apramycin Sulfate B1521 Varies 65710-07-8 Ascomycin 1573 2 mg 104987-12-4 Atpenin A5 (Synthetic) 2210 Varies 119509-24-9 Azithromycin B1226 Varies 83905-01-5 Bacitracin B1529 Varies 26048-05-5 Beauvericin B1246 Varies 26048-05-5 Blasticidin S Hydrochloride 1859 Varies 3513-03-9 EZSolution™ Blasticidin S Hydrochloride, Sterile-Filtered 2805 10 ml 3513-03-9 Bleomycin sulfate 2246 Varies 9041-93-4 Brefeldin A 1560 Varies 20350-15-6 Carbenicillin disodium 2485 Varies 4800-94-6 Caspofungin acetate 2584 Varies 179463-17-3 Cefotaxime Sodium, USP B1510 Varies 64485-93-4 Cefsulodin Sodium Salt, Hydrate B1512 Varies 52152-93-9 Ceftazidime B1523 Varies 72558-82-8 Cefsulodin Sodium Salt, Hydrate B1512 Varies 52152-93-9 Cephalexin Hydrate B1522 Varies 15686-71-2 Cefazolin Sodium Salt B1530 Varies 27164-46-1 Chloramphenicol 2486 Varies 56-75-7 EZSolution™ Chloramphenicol, Sterile-Filtered 2500 10 ml 56-75-7 Clindamycin hydrochloride 2627 Varies 21462-39-5 Colistin Sulfate 9696 Varies 1264-72-8 Cycloheximide (100 mM) 1041 Varies 66-81-9 Cyclosporine A 1522 Varies 59865-13-3 Dalbavancin 2852 Varies 171500-79-1 Daptomycin 2582 Varies 103060-53-3 Daunorubicin.HCl 1524 Varies 23541-50-6 Doxorubicin.HCl 1527 5 mg 25316-40-9 Doxycycline hyclate 2209 Varies 24390-14-5 Erythromycin 9619 Varies 114-07-8 Fidaxomicin 2832 Varies 873857-62-6 G418 Sulfate 1557 Varies 108321-42-2 EZSolution™ G418 Sulfate 2864 Varies 108321-42-2 Geldanamycin 1564 Varies 30562-34-6 Gentamicin sulfate B1270 Varies 1405-41-0 Hygromycin B 2589 Varies 31282-04-9 EZSolution™ Hygromycin B 2590 20 ml 31282-04-9 Ionomycin (free acid) 1565 Varies 56092-81-0 Ionomycin (Calcium salt) 1566 Varies 56092-82-1 Kanamycin Sulfate, USP 2498 Varies 25389-94-0 Kirromycin B1236 Varies 50935-71-2 Lincomycin Hydrochloride B1524 Varies 859-18-7 Metronidazole 9522 Varies 443-48-1 Micafungin sodium 2585 Varies 208538-73-2 www.biovision.com Mitomycin C 2713 Varies 50-07-7 www.biovision.com Minocycline Hydrochloride B1525 Varies 13614-98-7 2 Product Name Cat. No. Size CAS # Product Name Cat. No. Size CAS # EZSolution™ Ampicillin sodium, Sterile-Filtered 2499 10 ml 69-52-3 Mithramycin A B1532 Varies 18378-89-7 Ampicillin trihydrate 2483 Varies 7177-48-2 Neomycin sulfate 9620 Varies 1405-10-3 Anisomycin 1549 10 mg 22862-76-6 Nourseothricin sulfate 2882 Varies 96736-11-7 Apramycin Sulfate B1521 Varies 65710-07-8 Novobiocin Sodium Salt B1526 Varies 1476-53-5 Ascomycin 1573 2 mg 104987-12-4 Nystatin, USP B1509 Varies 1400-61-9 Atpenin A5 (Synthetic) 2210 Varies 119509-24-9 Oxytetracycline Hydrochloride B1527 Varies 2058-46-0 Azithromycin B1226 Varies 83905-01-5 Paromomycin Sulfate B1528 Varies 1263-89-4 Bacitracin B1529 Varies 26048-05-5 Penicillin G potassium, USP 2504 Varies 113-98-4 Beauvericin B1246 Varies 26048-05-5 Penicillin G sodium 2503 Varies 69-57-8 Blasticidin S Hydrochloride 1859 Varies 3513-03-9 EZSolution™ Penicillin/Streptomycin, Sterile-Filtered (100X) 2502 100 ml 61-33-6; 57-92-1 EZSolution™ Blasticidin S Hydrochloride, Sterile-Filtered 2805 10 ml 3513-03-9 EZSolution™ Penicillin/Streptomycin/Amphotericin B, Sterile-Filtered 61-33-6; 57-92-1; 2505 100 ml Bleomycin sulfate 2246 Varies 9041-93-4 (100X) 1397-89-3 Brefeldin A 1560 Varies 20350-15-6 Phleomycin 2724 Varies 11006-33-0 Carbenicillin disodium 2485 Varies 4800-94-6 EZSolution™ Phleomycin B1531 Varies 11006-33-0 Caspofungin acetate 2584 Varies 179463-17-3 Polymyxin B sulfate 2496 Varies 1405-20-5 Cefotaxime Sodium, USP B1510 Varies 64485-93-4 Puromycin Dihydrochloride 1860 Varies 58-58-2 Cefsulodin Sodium Salt, Hydrate B1512 Varies 52152-93-9 EZSolution™Puromycin Dihydrochloride 1861 100 mg 58-58-2 Ceftazidime B1523 Varies 72558-82-8 Rifampicin B1511 Varies 13292-46-1 Cefsulodin Sodium Salt, Hydrate B1512 Varies 52152-93-9 Roxithromycin 9621 Varies 80214-83-1 Cephalexin Hydrate B1522 Varies 15686-71-2 Radicicol B1533 Varies 12772-57-5 Cefazolin Sodium Salt B1530 Varies 27164-46-1 Sclerotiorin 2334 Varies 549-23-5 Chloramphenicol 2486 Varies 56-75-7 Solithromycin B1222 Varies 760981-83-7 EZSolution™ Chloramphenicol, Sterile-Filtered 2500 10 ml 56-75-7 Spectinomycin Dihydrochloride Pentahydrate 9524 Varies 22189-32-8 Clindamycin hydrochloride 2627 Varies 21462-39-5 Staurosporine 1048 Varies 62996-74-1 Colistin Sulfate 9696 Varies 1264-72-8 EZSolution™ Staurosporine 1745 100 μg 62996-74-1 Cycloheximide (100 mM) 1041 Varies 66-81-9 Streptomycin Sulfate 2517 Varies 3810-74-0 Cyclosporine A 1522 Varies 59865-13-3 Streptozocin 1930 Varies 18883-66-4 Dalbavancin 2852 Varies 171500-79-1 Sulfamethoxazole B1534 Varies 723-46-6 Daptomycin 2582 Varies 103060-53-3 Teicoplanin 1756 Varies 61036-62-2 Daunorubicin.HCl 1524 Varies 23541-50-6 Tetracycline Hydrochloride B1535 Varies 64-75-5 Doxorubicin.HCl 1527 5 mg 25316-40-9 Thapsigargin 1558 1 mg 1558-1 Doxycycline hyclate 2209 Varies 24390-14-5 Thiostrepton 9677 Varies 1393-48-2 Erythromycin 9619 Varies 114-07-8 Ticarcillin Disodium B1536 Varies 4697-14-7 Fidaxomicin 2832 Varies 873857-62-6 Tigecycline 1956 Varies 220620-09-7 G418 Sulfate 1557 Varies 108321-42-2 Tildipirosin 9673 Varies 328898-40-4 EZSolution™ G418 Sulfate 2864 Varies 108321-42-2 Timentin B1508 Varies 4697-14-7; 61177-45-5 Geldanamycin 1564 Varies 30562-34-6 Tobramycin B1537 Varies 32986-56-4 Gentamicin sulfate B1270 Varies 1405-41-0 Tobramycin Sulfate B1538 Varies 79645-27-5, 49842-07-1 Hygromycin B 2589 Varies 31282-04-9 Trichostatin A 1606 1 mg 58880-19-6 EZSolution™ Hygromycin B 2590 20 ml 31282-04-9 Trimethoprim Lactate B1539 Varies 23256-42-0 Ionomycin (free acid) 1565 Varies 56092-81-0 Tunicamycin 2802 Varies 11089-65-9 Ionomycin (Calcium salt) 1566 Varies 56092-82-1 Validamycin A B1540 Varies 37248-47-8 Kanamycin Sulfate, USP 2498 Varies 25389-94-0 Vancomycin Hydrochloride B1507 Varies 1404-93-9 Kirromycin B1236 Varies 50935-71-2 Lincomycin Hydrochloride B1524 Varies 859-18-7 We are constantly adding new products in this field to provide a complete product portfolio for your Metronidazole 9522 Varies 443-48-1 research. Please visit our website, www.biovision.com for the most up-to-date details on all the prod- Micafungin sodium 2585 Varies 208538-73-2 ucts that we have in our catalog. Mitomycin C 2713 Varies 50-07-7 www.biovision.com Minocycline Hydrochloride B1525 Varies 13614-98-7 For ordering please email us at: [email protected] 2 3.
Load more

Recommended publications
  • The Role of Nanobiosensors in Therapeutic Drug Monitoring
    Journal of Personalized Medicine Review Personalized Medicine for Antibiotics: The Role of Nanobiosensors in Therapeutic Drug Monitoring Vivian Garzón 1, Rosa-Helena Bustos 2 and Daniel G. Pinacho 2,* 1 PhD Biosciences Program, Universidad de La Sabana, Chía 140013, Colombia; [email protected] 2 Therapeutical Evidence Group, Clinical Pharmacology, Universidad de La Sabana, Chía 140013, Colombia; [email protected] * Correspondence: [email protected]; Tel.: +57-1-8615555 (ext. 23309) Received: 21 August 2020; Accepted: 7 September 2020; Published: 25 September 2020 Abstract: Due to the high bacterial resistance to antibiotics (AB), it has become necessary to adjust the dose aimed at personalized medicine by means of therapeutic drug monitoring (TDM). TDM is a fundamental tool for measuring the concentration of drugs that have a limited or highly toxic dose in different body fluids, such as blood, plasma, serum, and urine, among others. Using different techniques that allow for the pharmacokinetic (PK) and pharmacodynamic (PD) analysis of the drug, TDM can reduce the risks inherent in treatment. Among these techniques, nanotechnology focused on biosensors, which are relevant due to their versatility, sensitivity, specificity, and low cost. They provide results in real time, using an element for biological recognition coupled to a signal transducer. This review describes recent advances in the quantification of AB using biosensors with a focus on TDM as a fundamental aspect of personalized medicine. Keywords: biosensors; therapeutic drug monitoring (TDM), antibiotic; personalized medicine 1. Introduction The discovery of antibiotics (AB) ushered in a new era of progress in controlling bacterial infections in human health, agriculture, and livestock [1] However, the use of AB has been challenged due to the appearance of multi-resistant bacteria (MDR), which have increased significantly in recent years due to AB mismanagement and have become a global public health problem [2].
    [Show full text]
  • WHO Drug Information Vol
    WHO Drug Information Vol. 31, No. 3, 2017 WHO Drug Information Contents Medicines regulation 420 Post-market monitoring EMA platform gains trade mark; Automated 387 Regulatory systems in India FDA field alert reports 421 GMP compliance Indian manufacturers to submit self- WHO prequalification certification 421 Collaboration 402 Prequalification process quality China Food and Drug Administration improvement initiatives: 2010–2016 joins ICH; U.S.-EU cooperation in inspections; IGDRP, IPRF initiatives to join 422 Medicines labels Safety news Improved labelling in Australia 423 Under discussion 409 Safety warnings 425 Approved Brimonidine gel ; Lactose-containing L-glutamine ; Betrixaban ; C1 esterase injectable methylprednisolone inhibitor (human) ; Meropenem and ; Amoxicillin; Azithromycin ; Fluconazole, vaborbactam ; Delafloxacin ; Glecaprevir fosfluconazole ; DAAs and warfarin and pibrentasvir ; Sofosbuvir, velpatasvir ; Bendamustine ; Nivolumab ; Nivolumab, and voxilaprevir ; Cladribine ; Daunorubicin pembrolizumab ; Atezolizumab ; Ibrutinib and cytarabine ; Gemtuzumab ozogamicin ; Daclizumab ; Loxoprofen topical ; Enasidenib ; Neratinib ; Tivozanib ; preparations ; Denosumab ; Gabapentin Guselkumab ; Benznidazole ; Ciclosporin ; Hydroxocobalamine antidote kit paediatric eye drops ; Lutetium oxodotreotide 414 Diagnostics Gene cell therapy Hightop HIV home testing kits Tisagenlecleucel 414 Known risks Biosimilars Warfarin ; Local corticosteroids Bevacizumab; Adalimumab ; Hydroquinone skin lighteners Early access 415 Review outcomes Idebenone
    [Show full text]
  • Cytosolic Selection Systems to Study Protein Stability
    Cytosolic Selection Systems To Study Protein Stability Ajamaluddin Malik,* Antje Mueller-Schickert, James C. A. Bardwell Howard Hughes Medical Institute, Department of Molecular, Cellular and Developmental Biology, University of Michigan, Ann Arbor, Michigan, USA Here we describe biosensors that provide readouts for protein stability in the cytosolic compartment of prokaryotes. These bio- sensors consist of tripartite sandwich fusions that link the in vitro stability or aggregation susceptibility of guest proteins to the in vivo resistance of host cells to the antibiotics kanamycin, spectinomycin, and nourseothricin. These selectable markers confer Downloaded from antibiotic resistance in a wide range of hosts and are easily quantifiable. We show that mutations within guest proteins that af- fect their stability alter the antibiotic resistances of the cells expressing the biosensors in a manner that is related to the in vitro stabilities of the mutant guest proteins. In addition, we find that polyglutamine tracts of increasing length are associated with an increased tendency to form amyloids in vivo and, in our sandwich fusion system, with decreased resistance to aminoglycoside antibiotics. We demonstrate that our approach allows the in vivo analysis of protein stability in the cytosolic compartment with- out the need for prior structural and functional knowledge. http://jb.asm.org/ rotein folding has been intensely studied in vitro, providing us sion number WP_004614937). To eliminate expression of the toxic CcdB Pwith a detailed understanding of this process. However, the product present on this plasmid, we introduced a stop codon (TAA) by simplified conditions typically used in vitro (i.e., the use of single mutating the tyrosine at amino acid position 5 of the ccdB gene.
    [Show full text]
  • Early-Life Antibiotic Use and Risk of Asthma and Eczema: Results of a Discordant Twin Study
    Early View Original article Early-life antibiotic use and risk of asthma and eczema: results of a discordant twin study Elise M.A. Slob, Bronwyn K. Brew, Susanne J.H. Vijverberg, Chantal J.A.R. Kats, Cristina Longo, Mariëlle W. Pijnenburg, Toos C.E.M. van Beijsterveldt, Conor V. Dolan, Meike Bartels, Patrick Magnusson, Paul Lichtenstein, Tong Gong, Gerard H. Koppelman, Catarina Almqvist, Dorret I. Boomsma, Anke H. Maitland-van der Zee Please cite this article as: Slob EMA, Brew BK, Vijverberg SJH, et al. Early-life antibiotic use and risk of asthma and eczema: results of a discordant twin study. Eur Respir J 2020; in press (https://doi.org/10.1183/13993003.02021-2019). This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Copyright ©ERS 2020 Early-life antibiotic use and risk of asthma and eczema: results of a discordant twin study Elise M.A. Slob1,2 Bronwyn K. Brew3,4 Susanne J.H. Vijverberg1,2 Chantal J.A.R. Kats1 Cristina Longo1 Mariëlle W. Pijnenburg5 Toos C.E.M. van Beijsterveldt6 Conor V. Dolan6 Meike Bartels6 Patrick Magnusson3 Paul Lichtenstein3 Tong Gong3 Gerard H. Koppelman7,8 Catarina Almqvist3,9 Dorret I. Boomsma6 Anke H. Maitland-van der Zee1,2* 1. Department of Respiratory Medicine, Amsterdam University Medical Centers, University of Amsterdam, P.O.
    [Show full text]
  • Gonorrhea, Chlamydia, and Syphilis
    2019 GONORRHEA, CHLAMYDIA, AND SYPHILIS AND CHLAMYDIA, GONORRHEA, Dedication TAG would like to thank the National Coalition of STD Directors for funding and input on the report. THE PIPELINE REPORT Pipeline for Gonorrhea, Chlamydia, and Syphilis By Jeremiah Johnson Introduction The current toolbox for addressing gonorrhea, chlamydia, and syphilis is inadequate. At a time where all three epidemics are dramatically expanding in locations all around the globe, including record-breaking rates of new infections in the United States, stakeholders must make do with old tools, inadequate systems for addressing sexual health, and a sparse research pipeline of new treatment, prevention, and diagnostic options. Lack of investment in sexual health research has left the field with inadequate prevention options, and limited access to infrastructure for testing and treatment have allowed sexually transmitted infections (STIs) to flourish. The consequences of this underinvestment are large: according to the World Health Organization (WHO), in 2012 there were an estimated 357 million new infections (roughly 1 million per day) of the four curable STIs: gonorrhea, chlamydia, syphilis, and trichomoniasis.1 In the United States, the three reportable STIs that are the focus of this report—gonorrhea, chlamydia, and syphilis—are growing at record paces. In 2017, a total of 30,644 cases of primary and secondary (P&S) syphilis—the most infectious stages of the disease—were reported in the United States. Since reaching a historic low in 2000 and 2001, the rate of P&S syphilis has increased almost every year, increasing 10.5% during 2016–2017. Also in 2017, 555,608 cases of gonorrhea were reported to the U.S.
    [Show full text]
  • Spontaneous Regression of Untreatable Mycoplasma Genitalium Urethritis
    Acta Derm Venereol 2015; 95: 732–733 SHORT COMMUNICATION Spontaneous Regression of Untreatable Mycoplasma genitalium Urethritis Harald Moi1,2, Aase Haugstvedt1 and Jørgen Skov Jensen3 1Olafia Clinic, Oslo University Hospital, Pb 4763, NO-0506 Oslo,2 Institute of Clinical Medicine, University of Oslo, Norway, and 3Microbiology and Infec- tion Control, STI, Research and Development, Statens Serum Institut, Copenhagen, Denmark. E-mail: [email protected] Accepted Jan 24, 2015; Epub ahead of print Jan 29, 2015 Mycoplasma genitalium is a sexually transmissible When specifically asked, he reported occasional discomfort from pathogen that causes non-gonococcal urethritis (NGU), the urethra. A prolonged doxycycline treatment, 100 mg 2 times cervicitis, and has been shown to cause rectal infections daily for 15 days was prescribed. A urethral sample for culture of M. genitalium was taken and sent to the Mycoplasma laboratory in men who have sex with men (1–3). The prevalence in Copenhagen. After nearly 6 months of culture, a strain of M. in men with symptomatic urethritis varies from 15% genitalium was isolated after inoculating Vero cells with the to 25% (4). Increasing rates of treatment failures with urethral swab sample, as previously described (9). azithromycin have been reported, and the widespread Five months after the initial treatment (April 2010), the patient use of azithromycin 1 g single-dose treatment for NGU returned for the fourth test of cure. A urethral smear showed a moderate urethritis. He admitted protected sexual contact with his is thought to trigger the selection of 23S rRNA gene mu- steady partner in East Asia after the last test.
    [Show full text]
  • NEW ANTIBACTERIAL DRUGS Drug Pipeline for Gram-Positive Bacteria
    NEW ANTIBACTERIAL DRUGS Drug pipeline for Gram-positive bacteria Françoise Van Bambeke, PharmD, PhD Paul M. Tulkens, MD, PhD Pharmacologie cellulaire et moléculaire Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium http://www.facm.ucl.ac.be Based largely on presentations given at the 24th and 25th European Congress of Clinical Microbiology and Infectious Diseases and the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy 22/05/2015 Gause Institute for New Antibiotics: the anti-Gram positive pipeline 1 Disclosures Research grants for work on investigational compounds discussed in this presentation from • Cempra Pharmaceuticals • Cerexa • GSK • Melinta therapeutics • The Medicine Company • MerLion Pharmaceuticals • Theravance • Trius 22/05/2015 Gause Institute for New Antibiotics: the anti-Gram positive pipeline 2 Belgium 22/05/2015 Gause Institute for New Antibiotics: the anti-Gram positive pipeline 3 Belgium 10 millions inhabitants … 10 Nobel prizes (10/850) • Peace - Institute of International Law, Ghent (1904) - Auguste Beernaert (1909) - Henri Lafontaine (1913) - Father Dominique Pire (1958) • Literature - Maurice Maeterlinck, Ghent (1911) • Medicine - Jules Bordet, Brussels (1919) - Corneille Heymans, Ghent (1938) - Christian de Duve, Louvain (1974) - Albert Claude, Brussels (1974) • Chemistry - Ilya Prigogyne, Brussels (1977) - Physics - François Englert, Brussels (2013) 22/05/2015 Gause Institute for New Antibiotics: the anti-Gram positive pipeline 4 The Catholic University of Louvain in brief (1 of 4) • originally founded in 1425 in the city of Louvain (in French and English; known as Leuven in Flemish) 22/05/2015 Gause Institute for New Antibiotics: the anti-Gram positive pipeline 5 The Catholic University of Louvain in brief (2 of 4) • It was one of the major University of the so-called "Low Countries" in the 1500 – 1800 period, with famous scholars and discoverers (Vesalius for anatomy, Erasmus for philosophy, …).
    [Show full text]
  • APO-Roxithromycin Roxithromycin Consumer Medicine Information
    APO-Roxithromycin Roxithromycin Consumer Medicine Information For a copy of a large print leaflet, Ph: 1800 195 055 What is in this leaflet · acute pharyngitis (sore throat and Before you take it discomfort when swallowing) This leaflet answers some common · tonsillitis When you must not take it questions about roxithromycin. It · sinusitis does not contain all the available Do not take this medicine if you information. It does not take the · acute bronchitis (infection of the have an allergy to: bronchi causing coughing) place of talking to your doctor or · roxithromycin pharmacist. · worsening of chronic bronchitis · any other macrolide antibiotics All medicines have risks and · pneumonia (lung infection (e.g. azithromycin, clarithromycin benefits. Your doctor has weighed characterised by fever, malaise, or erythromycin) the risks of you using this medicine headache) · any of the ingredients listed at the against the benefits they expect it · skin and soft tissue infections end of this leaflet will have for you. · non gonococcal urethritis Some of the symptoms of an allergic Ask your doctor or pharmacist: · impetigo (bacterial infection reaction may include: · if there is anything you do not causing sores on the skin) · shortness of breath understand in this leaflet, · wheezing or difficulty breathing · if you are worried about taking How it works your medicine, or · swelling of the face, lips, tongue, Roxithromycin is an antibiotic that throat or other parts of the body · to obtain the most up-to-date belongs to a group of medicines · rash, itching or hives on the skin information. called macrolides. You can also download the most up These antibiotics work by killing or Do not take this medicine if you to date leaflet from stopping the growth of the bacteria have severe liver problems.
    [Show full text]
  • WHO Report on Surveillance of Antibiotic Consumption: 2016-2018 Early Implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some Rights Reserved
    WHO Report on Surveillance of Antibiotic Consumption 2016-2018 Early implementation WHO Report on Surveillance of Antibiotic Consumption 2016 - 2018 Early implementation WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution- NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons. org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non- commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Danmap 2006.Pmd
    DANMAP 2006 DANMAP 2006 DANMAP 2006 - Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, foods and humans in Denmark Statens Serum Institut Danish Veterinary and Food Administration Danish Medicines Agency National Veterinary Institute, Technical University of Denmark National Food Institute, Technical University of Denmark Editors: Hanne-Dorthe Emborg Danish Zoonosis Centre National Food Institute, Technical University of Denmark Mørkhøj Bygade 19 Contents DK - 2860 Søborg Anette M. Hammerum National Center for Antimicrobials and Contributors to the 2006 Infection Control DANMAP Report 4 Statens Serum Institut Artillerivej 5 DK - 2300 Copenhagen Introduction 6 DANMAP board: National Food Institute, Acknowledgements 6 Technical University of Denmark: Ole E. Heuer Frank Aarestrup List of abbreviations 7 National Veterinary Institute, Tecnical University of Denmark: Sammendrag 9 Flemming Bager Danish Veterinary and Food Administration: Summary 12 Justin C. Ajufo Annette Cleveland Nielsen Statens Serum Institut: Demographic data 15 Dominique L. Monnet Niels Frimodt-Møller Anette M. Hammerum Antimicrobial consumption 17 Danish Medicines Agency: Consumption in animals 17 Jan Poulsen Consumption in humans 24 Layout: Susanne Carlsson Danish Zoonosis Centre Resistance in zoonotic bacteria 33 Printing: Schultz Grafisk A/S DANMAP 2006 - September 2007 Salmonella 33 ISSN 1600-2032 Campylobacter 43 Text and tables may be cited and reprinted only with reference to this report. Resistance in indicator bacteria 47 Reprints can be ordered from: Enterococci 47 National Food Institute Escherichia coli 58 Danish Zoonosis Centre Tecnical University of Denmark Mørkhøj Bygade 19 DK - 2860 Søborg Resistance in bacteria from Phone: +45 7234 - 7084 diagnostic submissions 65 Fax: +45 7234 - 7028 E.
    [Show full text]
  • Intracellular Penetration and Effects of Antibiotics On
    antibiotics Review Intracellular Penetration and Effects of Antibiotics on Staphylococcus aureus Inside Human Neutrophils: A Comprehensive Review Suzanne Bongers 1 , Pien Hellebrekers 1,2 , Luke P.H. Leenen 1, Leo Koenderman 2,3 and Falco Hietbrink 1,* 1 Department of Surgery, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands; [email protected] (S.B.); [email protected] (P.H.); [email protected] (L.P.H.L.) 2 Laboratory of Translational Immunology, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands; [email protected] 3 Department of Pulmonology, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands * Correspondence: [email protected] Received: 6 April 2019; Accepted: 2 May 2019; Published: 4 May 2019 Abstract: Neutrophils are important assets in defense against invading bacteria like staphylococci. However, (dysfunctioning) neutrophils can also serve as reservoir for pathogens that are able to survive inside the cellular environment. Staphylococcus aureus is a notorious facultative intracellular pathogen. Most vulnerable for neutrophil dysfunction and intracellular infection are immune-deficient patients or, as has recently been described, severely injured patients. These dysfunctional neutrophils can become hide-out spots or “Trojan horses” for S. aureus. This location offers protection to bacteria from most antibiotics and allows transportation of bacteria throughout the body inside moving neutrophils. When neutrophils die, these bacteria are released at different locations. In this review, we therefore focus on the capacity of several groups of antibiotics to enter human neutrophils, kill intracellular S. aureus and affect neutrophil function. We provide an overview of intracellular capacity of available antibiotics to aid in clinical decision making.
    [Show full text]
  • Preparation of an Antibiotic Crystalline Fusidic Acid
    (19) TZZ__T (11) EP 1 945 654 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07J 13/00 (2006.01) A61K 31/575 (2006.01) 19.08.2015 Bulletin 2015/34 A61P 31/00 (2006.01) (21) Application number: 06805540.9 (86) International application number: PCT/DK2006/000600 (22) Date of filing: 30.10.2006 (87) International publication number: WO 2007/051468 (10.05.2007 Gazette 2007/19) (54) PREPARATION OF AN ANTIBIOTIC CRYSTALLINE FUSIDIC ACID HERSTELLUNG EINER ANTIBIOTISCHEN KRISTALLINEN FUSIDINSÄURE PREPARATION D’UNE SUBSTANCE ANTIBIOTIQUE CRISTALLINE DE L’ ACIDE FUSIDIQUE (84) Designated Contracting States: • ANDERSEN, Niels, Rastrup AT BE BG CH CY CZ DE DK EE ES FI FR GB GR DK-2720 Vanløse (DK) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR (56) References cited: BE-A- 619 287 DE-A1- 1 468 178 (30) Priority: 31.10.2005 US 731247 P ES-A1- 2 204 331 ES-A1- 2 208 110 FR-A- 1 326 076 GB-A- 930 786 (43) Date of publication of application: RU-C2- 2 192 470 23.07.2008 Bulletin 2008/30 • HIKINO HIROSHI ET AL: "Fungal metabolites. II. (73) Proprietor: LEO PHARMA A/S Fusidic acid, a steroidal antibiotic from Isaria 2750 Ballerup (DK) kogane" CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF (72) Inventors: JAPAN, TOKYO, JP, vol. 20, no. 5, 1972, pages • JENSEN, Jan 1067-1069, XP008080392 ISSN: 0009-2363 DK-2980 Kokkedal (DK) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]